Biotechnology - Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 110 results

Samsung Bioepis' Enbrel biosimilar candidate SB4 accepted for review by EMA

Samsung Bioepis' Enbrel biosimilar candidate SB4 accepted for review by EMA

21-01-2015

South Korea’s Samsung Bioepis says that the Marketing Authorization Application for its Enbrel (etanercept)…

AmgenAnti-Arthritics/RheumaticsBiogen IdecBiosimilarsBiotechnologyEnbrelEuropePfizerRegulationSamsung Bioepis

Celgene’s oral Otezla approved by EC for psoriasis and psoriatic arthritis

Celgene’s oral Otezla approved by EC for psoriasis and psoriatic arthritis

18-01-2015

US biotech firm Celgene’s European subsidiary has received marketing authorization from the European…

Anti-Arthritics/RheumaticsBiotechnologyCelgene CorpDermatologicalsEuropeOtezlaRegulation

First ever regulatory approval of Novartis' Cosentyx, in Japan

First ever regulatory approval of Novartis' Cosentyx, in Japan

26-12-2014

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Swiss pharma giant Novartis’…

Anti-Arthritics/RheumaticsBiotechnologyCosentyxDermatologicalsJapanNovartisRegulation

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

09-12-2014

US pharma major Eli Lilly and partner Incyte Corp today revealed that the Phase III RA-BEACON study of…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteResearchUSA

NICE now proposes to recommend Stelara for psoriatic arthritis

NICE now proposes to recommend Stelara for psoriatic arthritis

09-12-2014

UK health cost watchdog, the National Institute for Health and Care Excellence (NICE) has opened a consultation…

Anti-Arthritics/RheumaticsBiotechnologyInflammatory diseasesJanssenJohnson & JohnsonPricingRegulationStelaraUK

PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug

04-12-2014

A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyinfliximabJohnson & JohnsonNew ZealandPricingRemicade

Lilly in-licenses Zosano’s osteo patch for up to $440 million

03-12-2014

Privately-held US biotech firm Zosano Pharma has entered into an exclusive agreement with pharma major…

Anti-Arthritics/RheumaticsBiotechnologyEli LillyLicensingZosano PharmaZP-PTH

Modern Biosciences announces RA R&D agreement with Janssen Biotech

Modern Biosciences announces RA R&D agreement with Janssen Biotech

27-11-2014

UK-based drug development company Modern Biosciences has entered into an R&D alliance and global option…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechLicensingModern BiosciencesUK

Stada Arz and mAbxience to negotiate over adalimumab biosimilar

21-11-2014

German drugmaker Stada Arzneimittel and the biotech specialist mAbxience have agreed to negotiate over…

AbbVieadalimumabAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyHumiraLicensingMabxienceSTADA Arzneimittel

Janssen and HemoShear identify vascular health benefits of RA drugs

Janssen and HemoShear identify vascular health benefits of RA drugs

11-11-2014

US biotech firm HemoShear and Janssen Research and Development plan to report data showing that a subset…

ActemraAnti-Arthritics/RheumaticsBiotechnologyCardio-vascularHemoShearJanssen Research and DevelopmentJohnson & JohnsonResearchRochesirukumabUSA

AstraZeneca to showcase inflammation/ autoimmunity pipeline at ACR

AstraZeneca to showcase inflammation/ autoimmunity pipeline at ACR

11-11-2014

Anglo-Swedish pharma major AstraZeneca, with its global biologics R&D subsidiary MedImmune, will present…

anifrolumabAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseaseslesinuradMavrilimumabMedImmuneResearchSifalimumabUSA

BioOutsource preparing for biosimilars boom

03-11-2014

Scotland, UK-based vaccine and microbiological testing company BioOutsource today announced a major initiative…

Anti-Arthritics/RheumaticsBioOutsourceBiosimilarsBiotechnologyResearchRespiratory and Pulmonary

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Auxilium's supplemental Biologics Application for Xiaflex approved by FDA

Auxilium's supplemental Biologics Application for Xiaflex approved by FDA

21-10-2014

Specialty biopharma company Auxilium Pharmaceuticals has received approval from the US Food And Drug…

Anti-Arthritics/RheumaticsAuxilium PharmaceuticalsBiotechnologyRegulationUSAXiaflex

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

09-10-2014

US biotech major Amgen says its Phase III study evaluating the efficacy and safety of its biosimilar…

AbbVieABP 501AmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyDermatologicalsHumiraResearchUSA

Biotherapies could save millions of euros when treating auto-immune diseases

Biotherapies could save millions of euros when treating auto-immune diseases

08-10-2014

Health care providers could save millions of euros if biotherapies were used in the treatment of Crohn’s…

Anti-Arthritics/RheumaticsBiotechnologyEuropeFinancialHealthcareResearchTheradiag

Amgen updates on Prolia in postmenopausal osteoporosis

Amgen updates on Prolia in postmenopausal osteoporosis

16-09-2014

USA-based Amgen has released results from a new exploratory analysis of the open-label extension study…

AmgenAnti-Arthritics/RheumaticsBiotechnologyProliaResearchWomen's Health

Premium-price biologicals and novel therapies will drive psoriatic arthritis market growth

10-09-2014

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in…

AbbVieAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyEli LillyEuropeHumiraJapanMarkets & MarketingNovartisOtezlaStelaraUSAXeljanz

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

03-09-2014

USA-based drug developer Alder BioPharmaceuticals says it has regained the worldwide rights to clazakizumab,…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbclazakizumabGlobalInflammatory diseasesLicensing

J&J affiliate Cilag GmbH International acquires Covagen

J&J affiliate Cilag GmbH International acquires Covagen

25-08-2014

Cilag GmbH International, an affiliate of US health care giant Johnson & Johnson’s Janssen companies,…

Anti-Arthritics/RheumaticsBiotechnologyCilag GmbH InternationalCovagenFynomAbInflammatory diseasesJanssenJohnson & JohnsonMergers & Acquisitions

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

21-08-2014

Surveyed managed care organizations (MCOs) anticipate that their costs of covering biologic treatments…

Anti-Arthritics/RheumaticsBiotechnologyFinancialHealthcareImmunologicals

Daiichi Sankyo initiates testing of etanercept biosimilar in Japan

Daiichi Sankyo initiates testing of etanercept biosimilar in Japan

20-08-2014

Japanese drug major Daiichi Sankyo says it has started the Phase III trial of CHS-0214, an investigational…

Active rheumatoid arthritisAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyCoherus BioSciencesDaiichi SankyoEnbreletanerceptJapanPharmacologyResearchRheumatoid arthritis

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

09-07-2014

Shares of US biotech firm Celgene fell 3.5% in premarket trade, but were up 1.2% $86.75 by mid-morning…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneOtezlaResearchUSA

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

18-06-2014

China-based biotech firm 3SBio has entered into an exclusive license with Selecta Biosciences for pegsiticase…

3SBioAnti-Arthritics/RheumaticsBiotechnologyLicensingpegsiticaseSelecta Biosciences

1 to 25 of 110 results

COMPANY SPOTLIGHT

Menarini

Back to top